A newly published study linking HIV medication to reduction in COVID-19 risk has many problems, experts warn.
June 18, 2020: Existing evidence-based interventions aren't enough to close HIV's racial gap; transgender patient outcomes in the HIV care continuum; meeting long-term needs of formerly incarcerated people; acute respiratory illness severity and HIV status.
Kaiser Permanente’s 2-1-1 pre-exposure prophylaxis (PrEP) program shows event-driven dosing works.
June 11, 2020: Diagnosis rates within a year of infection; rates of intentional non-daily PrEP use; neurological development in children of birth parents with HIV; point-of-care urine test to assess tenofovir levels.
May 21, 2020: PrEP demographics by health insurance claim data; pediatricians call for better PrEP formulations for teens; weight gain after switching from TDF to TAF; two-drug regimen efficacy when baseline viral load is high.
Investigational PrEP Injection, Dosed Every Other Month, Holds Up Against Daily PrEP in Phase 3 Study
The long-acting injectable drug cabotegravir proved non-inferior to daily oral TDF/FTC for MSM and transgender women.
Home HIV and STI testing is now being endorsed by the Centers for Disease Control and Prevention to start or continue pre-exposure prophylaxis (PrEP).
COVID-19 Impacts Gay and Bisexual Men's Mental Health, Sexual Behavior, and Access to HIV/STI Services
This new study is the first to look at the impacts of the coronavirus pandemic on men who have sex with men.
May 7, 2020: Epidemiological factors among transgender women; revised PrEP indication estimates for MSM; trends in HIV strain similarity between younger and older MSM; current hepatitis C epidemic among British MSM with HIV.
April 30, 2020: Substance use relapse following opioid therapy for chronic pain; affect of cannabis on blood-brain barrier disruptions; PrEP considerations for adolescents; updated CDC contraceptive recommendations for women at risk for HIV.